Education
About Us
Working with TipRanks
Follow Us
Galapagos (GLPG)
NASDAQ:GLPG
GLPG Stock Chart & Stats
$33.66
-$0.67(-2.33%)
At close: 4:00 PM EST
$33.66
-$0.67(-2.33%)
Day’s Range― - ―
52-Week Range$22.59 - $37.78
Previous CloseN/A
Volume251.83K
Average Volume (3M)110.39K
Market Cap
$2.21B
Enterprise Value$1.80B
Total Cash (Recent Filing)$3.00B
Total Debt (Recent Filing)$12.10M
Price to Earnings (P/E)5.6
Beta0.75
Next Earnings
May 06, 2026EPS Estimate
-1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)13.99
Shares Outstanding65,897,070
10 Day Avg. Volume99,472
30 Day Avg. Volume110,389
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.57
Price to Sales (P/S)1.66
P/FCF Ratio-9.10
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue1.62
Enterprise Value/Gross Profit2.88
Enterprise Value/Ebitda6.15
Forecast
1Y Price Target
$27.50Price Target Upside-18.30% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)-2.26
Revenue Forecast (FY)$244.36M
Bulls Say, Bears Say
Bulls Say
Balance Sheet ValuationAnalyst upgrade indicates the company could trade closer to its cash balance as markets reassess a lower-spend profile.
Operating Expense ReductionManagement's decision to wind down the cell therapy unit is expected to remove the majority of the current burn rate and materially cut operating expenses.
Strategic Focus And Business DevelopmentRenewed cost discipline and program prioritization improve the company's readiness to pursue targeted business development or licensing opportunities.
Bears Say
Operational Disruption From Site ClosuresShutting down all non-headquarters sites risks disrupting ongoing research activities and may delay progress on remaining programs.
Restructuring Costs And LiabilitiesLarge-scale layoffs and site closures are likely to generate one-time restructuring expenses and potential severance or legal liabilities.
Workforce Reduction ImpactWind-down of the cell therapy business will impact 365 employees and could create reputational and morale challenges across the organization.
Galapagos News
GLPG FAQ
What was Galapagos’s price range in the past 12 months?
Galapagos lowest stock price was $22.59 and its highest was $37.78 in the past 12 months.
What is Galapagos’s market cap?
Galapagos’s market cap is $2.21B.
When is Galapagos’s upcoming earnings report date?
Galapagos’s upcoming earnings report date is May 06, 2026 which is in 65 days.
How were Galapagos’s earnings last quarter?
Galapagos released its earnings results on Feb 23, 2026. The company reported $13.993 earnings per share for the quarter, beating the consensus estimate of -$0.127 by $14.12.
Is Galapagos overvalued?
According to Wall Street analysts Galapagos’s price is currently Overvalued.
Does Galapagos pay dividends?
Galapagos does not currently pay dividends.
What is Galapagos’s EPS estimate?
Galapagos’s EPS estimate is -1.15.
How many shares outstanding does Galapagos have?
Galapagos has 65,897,070 shares outstanding.
What happened to Galapagos’s price movement after its last earnings report?
Galapagos reported an EPS of $13.993 in its last earnings report, beating expectations of -$0.127. Following the earnings report the stock price went up 1.447%.
Which hedge fund is a major shareholder of Galapagos?
Currently, no hedge funds are holding shares in GLPG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Galapagos Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$27.50 (-18.30% Downside)
$27.50 (-18.30% Downside)
Hedge Fund Trend
Decreased
By 18.5K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.37%
12-Months-Change
Fundamentals
Return on Equity
-16.45%
Trailing 12-Months
Asset Growth
-11.38%
Trailing 12-Months
Company Description
Galapagos
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
GLPG Company Deck
GLPG Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balances strong strategic positives — a ~EUR 3.0 billion cash position, a return to operating profit in 2025 (driven by a EUR 1,069 million deferred income release), a positive Phase II topline for GLPG3667 in dermatomyositis, a refreshed leadership team and an active business-development pipeline — against meaningful near-term headwinds including large one-time impairment and wind-down charges (EUR ~399.8 million impact), a year-over-year cash decline (~9.6%), and chunky restructuring and wind-down cash outflows expected in 2026 (EUR 125–175 million plus additional costs). The operating profit is largely non-recurring accounting-driven, and execution risk remains around BD activity, TYK2 pathway decisions, and restoring investor confidence. Overall, highlights slightly outweigh lowlights given the strong balance sheet, strategic clarity and positive clinical result, but material near-term costs and uncertainty temper the outlook.View all GLPG earnings summariesGLPG Stock 12 Month Forecast
Average Price Target
$27.50
▼(-18.30% Downside)
Technical Analysis
Agios Pharma
―
Travere Therapeutics
―
Disc Medicine
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
―
Insiders
1.76% Mutual Funds
41.41% Other Institutional Investors
56.21% Public Companies and
Individual Investors